OBJECTIVES The aim of this study was to explore the safety and efficacy of a dedicated drug-eluting stent for the treatment of coronary lesions with very small reference vessel diameter (RVD).
be symptomatic (4, 5) . Furthermore, data suggest that side-branch occlusion of small coronary vessels can lead to myocardial infarction that in turn is associated with higher mortality and future adverse cardiac events (6, 7) . Coronary artery bypass grafting is performed successfully on vessels $1.5 mm in diameter, demonstrating the belief among the cardiac surgery community that coronary vessels with RVD between 1.5 and 2.25 mm may sustain important areas of myocardium (8) .
It is unclear whether the excellent outcomes with DES observed in smaller RVD (e.g., >2.25 mm) (9, 10) are also seen with extremely small diameters. After the procedure, subjects received maintenancedose aspirin 75 to 325 mg/day indefinitely and an oral P2Y 12 antagonist daily for at least 6 months and up to 12 months in subjects who were not at high risk for bleeding. Subjects were followed up at 30 days, Figure 2 . A total of 101 subjects with 104 lesions were enrolled ( Tables 1   and 2 ). The mean subject age was 67.3 AE 9.6 years, 70% were men, and 47% had diabetes. The target lesion involved the left anterior descending coronary artery in 37%, the left circumflex coronary artery in 37%, and the right coronary artery in 29% of cases.
The majority of lesions were anatomically complex (65% were type B2/C). The mean lesion length was 12.6 AE 6.3 mm and the mean RVD was 1.91 AE 0.26 mm by QCA. Per protocol, nearly all lesions (99%) were pre-dilated. Post-dilation was performed for 39% of implanted stents. Lesion success was 99.0%, device success was 96.2%, and procedure success was 97.0%.
At 12 months, 88% of subjects reported taking dualantiplatelet therapy.
CLINICAL OUTCOMES. At discharge, the rate of TLF was 2.0% (2 of 101), driven by target vessel myocardial infarction ( Table 3 ). There were no new events between discharge and 30 days. Follow-up at 12 months was available in 100 subjects (99%) (Figure 2 ).
The rate of 12-month TLF was 5.0% (5 of 100), fulfilling the pre-specified performance criterion ANGIOGRAPHIC OUTCOMES. A total of 26 subjects with 27 lesions participated in the angiographic substudy. The baseline characteristics of the subjects enrolled in the substudy were similar to those of the subjects who did not undergo angiographic followup, with the exception of hypertension and unstable angina, which were less frequently present (Online Table 1 ). Evaluable follow-up angiographic data were available for 24 subjects and 25 lesions ( Table 4) .
More than one-half of these subjects (57.7%) had In the present study, we studied the safety and efficacy of the R-Onyx 2.0 mm ZES, which is mounted on a balloon with a nominal pressure of 12 atm and is therefore sized appropriately for implantation within vessels with extremely small diameters. The study met its primary endpoint with a 5.0% rate of TLF at 12 months compared with the pre-specified performance goal of 19.0%, a criterion that is lower than the performance goal of 20.4% used to assess the 2.25-mm everolimus-eluting stent (11) and less than the 21.1% performance goal to assess the 2.25-mm platinum-chromium everolimus-eluting stent (10). 
